Dane Dickson
M.D., CEO, MED-C
Dr. Dickson graduated in 1992 from the University of Utah with a BA in chemistry and a minor in Mandarin Chinese. He attended medical school at the University of Utah graduating in 1996 with honors. Subsequently, he completed an internal medicine residency at Washington University in St. Louis in 1999. He specialized at the Huntsman Cancer Institute at the University of Utah.
In 2001, he started a solo practice (Teton Oncology) in Rexburg, Idaho, which eventually encompassed over 8,000 square miles of Idaho and Wyoming. In 2010, his small group practice was acquired by a local hospital, and Dr. Dickson spearheaded the development of the Teton Cancer Institute and served as its Medical Director until 2014.
Also in 2001, he started the Summarius Corporation, a medical informatics company specializing in clinical trial review and development of OIG compliant materials for education and training. Summarius developed revolutionary methods of summarizing and presenting clinical trials and revised the complete training and educational materials for fortune 100 pharmaceutical companies.
In 2012, he started working with Noridian LLC, a Medicare Administrative Contractor, as an oncology subject matter expert, and then in 2013 he accepted, as a contractor, the position of Director of Clinical Science for the Molecular Diagnostic Program (MolDX) with Palmetto GBA (another CMS MAC contractor). In this capacity, he advises Palmetto on policy for implementation of molecular testing and personalize medicine policy from a clinical perspective.
In 2014, multiple groups recognized a substantial unmet need in the advancement of personalized medicine, and the Molecular Evidence Development Consortium (MED-C) was conceived. It was vetted in various groups where it was highly acclaimed and warmly received by clinicians, laboratories, payors, industry, pharma, patient groups and regulators. In 2015, after extensive searching by and finding no existing group that could implement this unmet need, the non-profit public charity (MED-C.org) was formed. Its mission is to advance personalized medicine through data collection and education. Its strength is brining all the major stakeholders together to work in a shared and scientific manner. MED-C continues to gain traction as a “transformative effort that will dramatically advance health care in the world.” Dr. Dickson has been asked to be its CEO.
Dr. Dickson has been an active member of the American Society of Clinical Oncology (ASCO). He served on ASCO’s Clinical Practice Committee from 2002-2005. In 2011, he helped revive the Idaho Society of Clinical Oncology (ISCO) and served as President from 2012-2014. He was elected to the executive sub-committee of the ASCO State Affiliate Council in 2013 and in 2014.
